Using advanced nanomedicine for therapy innovation

At a Glance

  • Founded: 1997, headquartered in Berlin, Germany
  • Management: Prof. Dr. Hoda Tawfik (COO and Co-CEO), Christian von Volkmann (CFO and Co-CEO)
  • Employees: 18 employees as well as a production company with 8 employees
  • Listed on Frankfurt Stock Exchange, (MF6)
  • Strong IP protection: 17 international patent families, approx. 100 single patents and 65 patent applications
  • Product launch of NanoTherm® therapy in 2011

Recent Highlights

  • Establishment of the first NanoTherm® therapy treatment center at the Charite-Universitätsmedizin Berlin, Clinic for Radiooncology, Campus Virchow
  • Successful completion of efficacy study in patients with recurrent glioblastoma
  • Publication of study results in the Journal of Neuro-Oncology
  • European regulatory approval of the NanoTherm® therapy (CE European conformity marking)
  • Equity funding of approx € 24 million ($31 million) secured in 2010
  • Distribution agreement signed with DELRUS, a leading Russian medical devices distribution company, for market entry in Russia and TekGrup, a leading company for sales, after sales services and support of medical devicesfor market entry in Turkey, Iraq, Albania and Azerbaijan